Sareum is a clinical stage small molecule drug development company developing next generation kinase inhibitors for autoimmune disease and cancer.
29 December 2022
16 December 2022
16 December 2022
24 November 2022
TYK2/JAK1 inhibitor SDC-1801, targeting autoimmune diseases, is being prepared for first clinical studies
Sareum's innovative pipeline is focused on the TYK/JAK cell signalling family.
IMC AGM, Dec 2022
IMC SDC-1801 CTA submission, Aug 2022
BioTrinity, April 2022
IMC Half Year Results, Feb 2022
Sareum Limited
Unit 2A, Langford Arch
London Road, Pampisford
Cambridge CB22 3FX
United Kingdom
tel: +44 (0) 1223 497700
fax: +44 (0) 1223 497701
